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A Randomized, Controlled Trial of Catheter-Related Infectious Event
Rates Using Antibiotic-Impregnated Catheters Versus Conventional
Catheters in Pediatric Cardiovascular Surgery Patients
Elaine G. Cox, Chad A. Knoderer, Aimee Jennings, John W. Brown, Mark D. Rodefeld, Scott G. Walker, and Mark
W. Turrentine
We conducted a randomized, controlled clinical trial to determine whether a difference in catheterassociated
blood stream infection (CABSI) incidence existed between children who underwent cardiac
surgery and had a central venous catheter impregnated with minocycline and rifampin versus those
who had a conventional, nonimpregnated catheter after cardiac surgery. Due to a lower number of
infections than expected, the study was terminated early. Among 288 evaluable patients, the rates of
CABSI and line-related complications were similar between the 2 groups.

BACKGROUND

Central venous catheter (CVC) use is associated with high risk of catheter-associated blood
stream infection (CABSI), increases in morbidity and mortality, and is a significant cost driver.
These issues tend to be more complicated in children in whom dependence on central catheters
has increased because of limitations on access options. With technical issues compounding
placement in ill children, rate of catheter colonization is high and approximately 8% result in
infection [1]. Pediatric cardiac intensive care unit (PICU) patients are at higher risk for CABSI
because of the presence of multiple catheters, long hospitalization, increased transfusions, and
prolonged high levels of support, including extracorporeal membrane oxygenation (ECMO) [2].
Efforts to decrease hospital-associated infections intensified after CABSI was declared a “never
event” by the Centers for Medicare and Medicaid, and the effectiveness of antibioticimpregnated catheters in further reducing infections has gained much interest [3]. Because of the
paucity of controlled trials of antibiotic-impregnated catheters in children, efficacy and safety
questions remain. Our objective was to determine whether a difference in CABSI incidence
existed between CVCs impregnated with minocycline and rifampin (M/R) versus conventional,
nonimpregnated (C/S) catheters used in children after cardiac surgery.
METHODS
Patients were eligible for the study if they were <18 years of age, underwent cardiovascular
surgery from October 2006 to March 2010 at Riley Hospital for Children, and had a case
complexity that warranted a CVC placement for longer than 3 days. Exclusion criteria were as
follows: (1) drug allergy to minocycline, other tetracyclines, or rifampin; (2) ventricular assist
device therapy; (3) ECMO therapy; (4) cardiac transplant; (5) active infection; and (6) delayed
closure of sternum. The study was approved by the Institutional Review Board at Indiana
University.
The study was a prospective, randomized controlled trial. Patients undergoing cardiac surgery
who required placement of a double lumen central venous catheters (4 Fr, 8 cm, 5 Fr, 8 cm or 12
cm long: Cook Critical Care, Bloomington, IN) were randomized with 1:1 allocation to receive
either the M/R or the C/S catheter. Study catheters were assigned a random identification number
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(by Cook Critical Care) and packed in identical catheter trays. The randomization scheme
consisted of blocks of six identical catheter trays stocked with the above catheters in a
randomized sequence. Although the color of the SPECTRUM catheter was unique and visible to
the inserting physician at the time of implantation, it was not documented and was not visible
after it placement. Thus, the clinical and infection control teams were in effect blinded to study
arm into which each patient had been assigned. Catheters were inserted into the subclavian,
femoral, or jugular vein under full sterile conditions in 1 of 2 designated operating rooms by
cardiovascular surgeons and anesthesiologists only. Skin preparation was in compliance with
guidelines with betadine for those patients younger than 2 months of age, and ChloraPrep was
used for older patients. Full patient draping was used on every case. Surgery-related data
included placement location, inserting physician, cardiac defect, cardiac repair, cardiopulmonary
bypass time, ischemic time, cut time, and intraoperative antibiotic administration. Cefuroxime
was the standard postoperative antibiotic, which is routinely given at our hospital for
cardiovascular surgery prophylaxis and administered for 24 hours. Patients with an allergy
received either vancomycin or clindamycin prophylaxis. Postoperative care was done in the
PICU and the Heart Center step down unit managed by the pediatric cardiovascular team.
The standard of care for incisions included a semipermeable membrane dressing that was
changed every 96 hours. When present, gauze dressings were changed every 48 hours. Catheter
site assessment was made with each dressing change, and the surrounding area was disinfected
with a chlorhexidine solution. Administration sets and all add-on devices were changed routinely
every 96 hours and every 24 hours when blood or lipids were infused, per hospital policy.
The primary outcome measure was incidence of CABSI per 1000 catheter days per standard
terminology. All CABSIs were determined by hospital infection control specialists according to
accepted National Healthcare Safety Network criteria at the time of study. Quantitative cultures
and differential time to positivity were not available at the microbiology laboratory of the study
institution. A secondary outcome measure was episodes of clinical sepsis and/or infection with
identified source other than the CVC.
Daily evaluation through hospital discharge included fever, blood pressure, white blood cell
count, platelet count, glucose, arrhythmia, urine output, or additional antibiotic administration.
Any catheter related complication, including pneumothorax, thrombosis, occlusion,
displacement, leakage, fracture, or fragmentation, was recorded.
Categorical measures were tabulated, and treatment differences were assessed with a χ2 or
Fisher’s exact test. Continuous measures were summarized using means and standard deviations.
Analysis was performed on an intention-to-treat basis. According to protocol, a blinded interim
analysis was performed by an independent data safety monitoring board upon 50% (290 patients)
of study enrollment.
RESULTS
The total number of enrolled patients was 326 with 288 deemed evaluable. Reasons for exclusion
included: open chest (10), ECMO (5), inability to place catheter (16), catheter inadvertently
inserted in wrong vessel (3), preexisting infection (1), no assent obtained (1), biopatch instead of
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standard dressing (1), and study catheter placed and removed in the operating room (1). Groups
were evenly split between the 2 catheters (M/R = 146, C/S = 142). Demographics, RACHS-1
scores, and procedural information did not vary significantly between groups (Table 1). The
number of catheter days were similar (M/R = 866 and C/S = 828).
The number of infections was exactly the same with 3 in each group. Rates of CABSI in both
groups were quite small (M/R = 3.46/1000 catheter days and C/S = 3.62/1000 catheter days), and
there was no statistically significant difference between the 2 groups (95% confidence interval, –
3.4%–3.2%; P > .99). All 6 CABSIs were noted to occur in children <2 years of age. Three
infections occurred in the internal jugular location (M/R = 2 and C/S = 1), 2 in the femoral
location (C/S = 2), and 1 in the subclavian vein (M/R = 1). Organism and line day of infection
also were not significantly different between groups with Escherichia coli and Streptococcus
mitis in the M/R group on days 3 to 17; and coagulase-negative staphylococcus, methicillinsusceptible Staphylococcus aureus, and Candida albicans being recovered on days 5–11 in the
C/S catheters.
Table 1 Primary Results
M/R(n= 146)

C/S (n= 142)

P Value

Demographics
Age (month)a
Weight (kg)a
Gender (male) Cardiopulmonary bypass time (minutes)b Anesthesia
time (minutes)b Ischemic time (minutes)b Surgery duration
(minutes)b OR time (minutes)b

12 (6.6–29.3)
8.8 (6.5–13)
51.4% 97.6 ± 48.9 371.1 ±
73 43.3 ± 31.8 212.5 ± 77.2
371.8 ± 72.4

12.9 (5.9–42.3)
8.9 (5.8–13.7)
53.5% 103.9 ± 55.7 375.4 ±
87.0 43.9 ± 30.6 214.5 ± 82.8
376.3 ± 87.5

.88
.68
.72 .31 .64
.88 .84 .63

Outcomes
ICU daysa
3(2–4)
2 (1–4)
Total hospital duration (days)a
6(5–10)
6 (4–9)
Antibiotic daysa
6(3–11.5)
3.5 (2–7)
All complications
10.3%
12%
Hemothorax
0.7%
0%
Bleeding at catheter insertion site
1.4%
0%
Venous thrombosis (in cannulated blood vessel)
0%
0.7%
Catheter leak (requiring repair or removal)
2.1%
2.1%
Catheter displacement (requiring replacement)
0%
0.7%
Catheter occlusion (requiring removal or thrombectomy)
2.7%
3.5%
Other catheter-related complications
4.8%
7%
Abbreviations: C/S, nonimpregnated catheters; ICU, intensive care unit; OR, operating room; M/R, minocycline and rifampin-coated catheters.

.71
.74
.19
.7
>.99
.49
.49
>.99
.49
.74
.46

aData reported as median (interquartile range).
bData reported as mean (+/– standard deviation).

There were no statistically significant differences in catheter complications between groups as
shown in Table 1, and, overall, complications were rare in either group in every category.
Noncatheter-related infections did not differ between groups. There were 8 of 146 (rate = 9.24)
in the M/R group and 4 of 141 (rate = 8.48) in the C/S group (P = .38).
Results of the interim analysis demonstrated that the expected infection rate was substantially
less than postulated and resulted in no overall statistical difference with regard to infectious
outcomes between catheters. It was expected that the study would be highly unlikely to show a
statistical difference, even with the substantial additional enrollment, and was therefore stopped.

3

DISCUSSION
With an increasing focus on infection risk, central catheter bundles have been used in efforts to
prevent CABSI. Implementation has been effective in adults but there is limited evidence in
children. Berneholtz et al [4] demonstrated a reduction in CABSI rate from 7.7 to 1.4 after
implementation of such techniques, and others have shown benefits as well [5].
Utilization of chlrohexidine-silver-coated catheters led to a minimal decrease in CABSI that is
beyond that seen based on education alone [6]. Early studies demonstrated decreased catheter
colonization and were suggestive of decreased infection with a possible associated cost savings,
although [7, 8] the decreased microbe colonization could not be directly translated to decreased
infection [9, 10]. One observational trial in critically ill children demonstrated longer onset to
infection compared with conventional catheters [11].
Our study demonstrates no statistical differences in CABSI in children after cardiac surgery in
M/R compared with C/S catheters. CABSI secondary to a staphylococcal organism was not
observed in the M/R catheters. No infections occurred in patients older than 2 years of age and
none in the M/R catheters placed in the femoral location, often the easiest access in small
children. Further studies may be warranted to assess the impact that M/R catheters may have in
these populations. Our study raises the question that perhaps antibiotic-impregnated catheters
cannot lower CABSI rates further when they are already extremely low; however, in areas that
have applied measures without reaching the desired goals, there could be some benefit in adding
these catheters.
Anecdotally, practitioners have commented that the antibiotic-impregnated catheters are more
difficult to insert and have increased complications. Our data dispute this assertion because there
were no statistically significant differences in any of the complications when comparing M/R
versus C/S catheters. However, the study lacked sufficient power to make definitive statements
regarding complications.
During study enrollment, infection control led efforts to reduce the PICU CABSI rate and
resulted in a decrease in overall line infection rate from a monthly peak of 14.5 to a low of 0.0
and an average of less than 4 per 1000 catheter days during our study period. This reduction in
baseline CABSI resulted in the study being underpowered to detect a significant difference
between catheters and is a significant limitation, making it difficult to pinpoint the independent
impact of the catheters. Because of low rates of infection, only a large multicenter study is likely
to generate the numbers required for statistical power.
CONCLUSIONS
Our results indicate that the M/R catheter can be safely used in children, including those who
weigh less than 10 kg, despite no current US Food and Drug Administration guidelines for that
age group. No difference was observed in infectious outcomes between M/R and C/S central
venous line catheters, possibly due to the extremely low baseline infection rate. There is no
evidence that complications are increased with their use. Further studies with larger subject
enrollment may be necessary to definitively answer such questions.
4

References
1. Jonge RCJ, Polderman KH, Gemke RJ. Central venous catheter use in the pediatric patient: mechanical and infectious
complications. Pediatr Crit Care Med 2005; 6: 329–39.
2. Costello JM, Graham DA, Morrow DF, et al. Risk factors for central line-associated bloodstream infection in a pediatric
cardiac intensive care unit. Pediatr Crit Care Med. 2009; 10:453–9.
3. Donaldson MS. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press; 2000.
4. Berneholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit.
Crit Care Med 2004; 32: 2014–20.
5. Miller MR, Niedner MF, Huskins WC, et al. Reducing PICU central line-associated bloodstream infections: 3 year results.
Pediatrics 2011; 128:e1077–83.
6. Schuerer DJE, Zack JE, Thomas J, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an
intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial.
Surg Infect 2007; 8: 445–54.
7. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. NEJM
1999; 340:1–8.
8. Raad II, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of
catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med 1997; 127:267–74.
9. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream
infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002; 34:1232–42.
10. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated catheters prevent catheterrelated bloodstream
infection? Clin Infect Dis 2003; 37: 65–72.
11. Chelliah A, Heydon KH, Zaoutis TE, et al. Observational trial of antibiotic-coated central venous catheters in critically ill
pediatric patients. Pediatr Infect Dis J 2007; 26:816–20.

5

